Navigation Links
Merz Pharmaceuticals Introduces New Mederma(R) Stretch Marks Therapy Now Available in Drugstores Nationwide

GREENSBORO, N.C., Feb. 17 /PRNewswire/ -- Stretch marks can make even the most beautiful women feel insecure and self-conscious. Approximately 90% of pregnant women and 70% of adolescent females have stretch marks, and they also commonly occur in people who have lost weight within a brief time period. Although they pose no health risks, stretch marks can cause negative body image issues for women of all shapes and sizes. With new Mederma® Stretch Marks Therapy women now have an effective, clinically proven option to improve the appearance of their stretch marks.

From the makers of #1 doctor-recommended brand for scars for over a decade, Mederma® Stretch Marks Therapy is a patented formula that combines a unique blend of ingredients, including the proprietary botanical extract Cepalin®, hyaluronic acid and centella asiatica leaf extract. This advanced formula is dermatologist tested and clinically proven to reduce discoloration, improve texture and enhance skin's softness, with noticeable improvement in about 4 weeks, and optimum improvement in 12 weeks when used twice daily.

"Stretch marks are very common and occur when the skin is stretched beyond a certain degree, such as during pregnancy or in times of weight increase when the connective tissue can be disrupted and show unattractive red marks on the skin's surface," says Zoe Diana Draelos, MD, a clinical and research dermatologist based in High Point, North Carolina, with a special interest in problems associated with skin, hair and nails. "In the clinical trial, 80% of women noted visible improvement in their stretch marks compared to non treatment, with a trend toward improved elasticity."

"Stretch marks can be a nagging reminder to new moms who have worked hard to lose their baby weight," says Victoria Pericon of Mom Blog "An effective product that could help to improve the appearance of their stretch marks would provide a real confidence boost for these women," she added.

Mederma® Stretch Marks Therapy is effective for all the areas of the body where stretch marks occur, including the arms, abdomen and buttocks. For best results, Mederma® Stretch Marks Therapy should be used as directed twice a day for 12 weeks.

Mederma® Stretch Marks Therapy is sold in a 5.29-oz tube and retails for $39.99. It is now available at CVS, Walgreens and in other drugstores nationwide.

About Mederma®

The Mederma® family of products, including Mederma® Gel, Mederma® Cream plus SPF 30, and Mederma® for Kids, has a long tradition of efficacy. The #1 doctor- and pharmacist-recommended brand for scars, Mederma® helps reduce the appearance of scars resulting from surgery, injury, burns, and acne, making them softer, smoother, and less noticeable. To learn more, visit

About Merz Pharmaceuticals

Merz Pharmaceuticals, LLC, a wholly owned, U.S. subsidiary of the Merz Group of Companies was established in 1995 and develops and commercializes prescription products for Neurology, Dermatology, Podiatry and the #1 non-prescription product for scars, Mederma®.

With a 101 year heritage, Merz (KGaA) is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in the development of pharmaceuticals for the treatment of neurological and psychological disorders as well as for aesthetic medicine, including products for the treatment of wrinkles and aging skin, hair loss and acne. Research is concentrated in fields that have a strong need for therapeutic innovation such as Alzheimer's disease, Parkinson's disease, tinnitus, chronic pain conditions, addictions, and neuromuscular disturbances.

SOURCE Merz Pharmaceuticals, LLC



SOURCE Merz Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
(Date:11/30/2015)... Nov. 30, 2015  PTS Diagnostics, the U.S.-based manufacturer ... analyzers, A1CNow ® systems, and PTS Detect™ ... of patents that will propel the company into the ... Europe . The technology is a ... those on smartphones and tablets, and uses test strip ...
(Date:11/30/2015)... , Nov. 30, 2015 Oramed Pharmaceuticals ... focused on the development of oral drug delivery systems, ... agreements valued at up to $50,000,000 with Hefei Tianhui Incubator of Technologies ... oral insulin capsule, ORMD-0801, in China ... Macau . The agreements were signed at ...
(Date:11/30/2015)... , Nov. 30, 2015 Cumberland Pharmaceuticals (CPIX), today ... live at on December 3, 2015. TIME: ... TIME: 3:15p.m. ET LINK: --> ... --> ... where investors are invited to ask the company questions in ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... The recently published 32nd ... System (NPDS) reveals that in 2014, someone called a poison center about every ... of which were human exposure cases. , The American Association of Poison Control ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... promoting breast and prostate cancer education and prevention—is joining forces with the award-winning ... philanthropy and Hollywood elegance on December 7, 2015 at the Union League of ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Reports magazine, quoted Michael Hansen, Ph.D., a senior scientist at Consumer Reports as ... more so for a child’s exposure limits. , The original Nov 2015 CR ...
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, Va., ... womb. "My last baby had high blood pressure due to loud noises," she said, ... their babies from noise pollution as well as radio waves and microwaves." , The ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... automated breast density assessment and enterprise analytics solutions, here at the 101st ... (South Hall booth #2377). Volpara’s quantitative breast imaging tools enable personalized measurements ...
Breaking Medicine News(10 mins):